Supplementary Data1 from Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer

Authors

Yu Wang (ORCID: https://orcid.org/0000-0002-2819-4551)
Melinda E. Sanders (ORCID: https://orcid.org/0000-0001-7227-1764)
Paula I. González-Ericsson (ORCID: https://orcid.org/0000-0002-6292-6963)
Violeta Sánchez (ORCID: https://orcid.org/0000-0001-6639-9024)
Erica Stringer-Reasor (ORCID: https://orcid.org/0000-0002-1862-3367)
Guadalupe Garcia (ORCID: https://orcid.org/0009-0002-3073-7495)
Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
Carlos L. Arteaga (ORCID: https://orcid.org/0000-0003-0870-9586)
Nisha G Unni (ORCID: https://orcid.org/0000-0003-1549-4720)
Ingrid A. Mayer (ORCID: https://orcid.org/0000-0001-8147-335X)
Brent N. Rexer (ORCID: https://orcid.org/0000-0002-0341-7392)
Brian D. Lehmann (ORCID: https://orcid.org/0000-0003-0407-5248)
Justin Micah Balko (ORCID: https://orcid.org/0000-0002-4263-5974)
Ben Ho Park (ORCID: https://orcid.org/0000-0001-8119-2291)
Qi Liu (ORCID: https://orcid.org/0000-0001-8892-7078)